Bristol-Myers Squibb Co (BMY.N) and Eisai Co said on Thursday they had entered into an agreement worth up to $3.10…
U.S. regulators on Monday approved Biogen Inc's (BIIB.O) aducanumab as the first treatment to attack a likely cause of Alzheimer's…